恩美曲妥珠单抗T-DM1在HER2阳性乳腺癌中的研究进展  

Research progress of T-DM1 in treatment of HER2 positive breast cancer

作　　者：李智慧(综述) 李志高(审校)[1] LI Zhihui;LI Zhigao(The Second Ward of Breast Surgery,Harbin Medical University Cancer Hospital,Harbin 150081,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院乳腺外科二病区,哈尔滨150081

出　　处：《实用肿瘤学杂志》2022年第5期477-482,共6页Practical Oncology Journal

摘　　要：T-DM1是由人源化单克隆抗体曲妥珠单抗通过连接子和细胞毒性药物DM1偶联形成的一种抗体-药物偶联物,综合了抗体的靶向性和细胞毒性药物的高效杀伤癌细胞特性,发挥双倍抗肿瘤效应的同时又降低了常规化疗药物的毒副反应。多项临床研究探索了T-DM1应用于晚期HER2阳性转移性乳腺癌的解救治疗以及早期HER2阳性乳腺癌的辅助化疗和新辅助化疗的有效性和耐受性,并展现出良好的临床应用前景。本文就T-DM1应用于HER2阳性乳腺癌的最新临床研究进展简要综述。Trastuzumab emtansine(T-DM1)is an antibody drug conjugate formed by the conjugation of humanized monoclonal antibody trastuzumab with cytotoxic drug DM1 through a linker,which integrates the targeting antibody and the high efficiency of cytotoxic drugs to kill cancer cells,exerts double anti-tumor effect and reduces the toxicity of conventional chemotherapeutic drugs.Several clinical studies have explored the effectiveness and tolerance of T-DM1 in rescue treatment of advanced HER2 positive metastatic breast cancer and adjuvant and neoadjuvant chemotherapy of early HER2 positive breast cancer,and shown a good clinical application prospects.This article briefly reviews the latest clinical research progress of T-DM1 in HER2 positive breast cancer.

关 键 词：T-DM1 HER2阳性乳腺癌 作用机制 临床研究 耐药机制 

分 类 号：R737.9[医药卫生—肿瘤]